Significant Publications #2
NOTE Disability: Including this publication except along with link to full article could be useful in applying for Disability as most U.S. doctors who review your claim will be unfamiliar with the condition. It explains the current and ongoing non-unified, non-collaborative work by PN specialists worldwide and that these issues have slowed or even stopped the study of the efficacy of treatments which elongates the suffering of woman and men with pudendal neuralgia.
​
​
​​Recommendations on the management of pudendal nerve entrapment [PNE]: A formalised expert consensus
​
Amélie Levesque 1, Eric Bautrant 2, Virginie Quistrebert 1, Guy Valancogne 3, Thibault Riant 4, Marc Beer Gabel 5, Anne-Marie Leroi 6, Katleen Jottard 7, Luc Bruyninx 7, Gerard Amarenco 8, Lara Quintas 9, Pascale Picard 10, Thierry Vancaillie 11, Christine Leveque 2, Frédérique Mohy 12, Bruno Rioult 4, Stéphane Ploteau 13, Jean-Jacques Labat 1, Amandine Guinet-Lacoste 14, Bertrand Quinio 15, Michel Cosson 16, Rebecca Haddad 8, Xavier Deffieux 17, Marie-Aimée Perrouin-Verbe 1, Claire Garreau 18, Roger Robert 4
2022 Jan;26(1):7-17. doi: 10.1002/ejp.1861. Epub 2021 Oct 13.​
Affiliations Expand
-
PMID: 34643963 © 2021 European Pain Federation - EFIC®. https://pubmed.ncbi.nlm.nih.gov/34643963/
-
DOI: 10.1002/ejp.1861​
Abstract [short summary]
​
Background: Since the development and publication of diagnostic criteria for pudendal nerve entrapment (PNE) syndrome in 2008, no comprehensive work has been published on the clinical knowledge in the management of this condition. The aim of this work was to develop recommendations on the diagnosis and the management of PNE.
Methods: The methodology of this study was based on French High Authority for Health Method for the development of good practice and the literature review was based on the PRISMA method. The selected articles have all been evaluated according to the American Society of Interventional Pain Physicians assessment grid.
​
Results: The results of the literature review and expert consensus are incorporated into 10 sections to describe diagnosis and management of PNE:
(1) Diagnosis of PNE
(2) Patients advice and precautions
(3) Drugs treatments
(4) Physiotherapy
(5) Transcutaneous Electrostimulations (TENS)
(6) Psychotherapy
(7) Injections
(8) Surgery
(9) Pulsed Radiofrequency [PRF]
(10) Neuromodulation [Neurostimulation] (e.g., PNS, SNS, DRG)
The following [seven] major points should be noted:
(i) The relevance of 4+1 Nantes criteria for diagnosis
(ii) The preference for initial monotherapy [a medical treatment that uses a single drug] with
tri-tetracyclics or gabapentinoids
(iii) The lack of effect of opiates
(iv) The likely relevance (pending more controlled studies) of physiotherapy1 (aka physical therapy2),
TENS and Cognitive Behavioural Therapy (CBT)
(v) The Incertitudes (lack of data) regarding Corticoid [Steroid] Injections
(vi) Surgery is a long-term effective treatment
(vii) Radiofrequency [PRF] needs a longer follow-up to be currently proposed in this indication
[meaning currently not proposed]
Conclusion: These recommendations should allow rational and homogeneous management (syn. uniform, consistent, identical) of patients suffering from PNE. They should also allow to shorten the delays of management by directing the primary care.
​
Significance: Pudendal nerve entrapment (PNE) has only been known for about 20 years and its [current] management is heterogeneous [syn. different, divergent, wide-ranging] from one practitioner to another. This work offers a synthesis of the literature and international experts' opinions on the diagnosis and management of PNE.
​
LINK to full POSITION PAPER summarized by abstract (Wiley Online Library Pages 1/11):
https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejp.1861 (must copy and paste)
​
CONFLICT OF INTEREST
A conflict of interest agreement was requested from each of the participating experts.
No conflicts of interest were declared by the authors.
​
​
​
​
​
_____
Pudendal Neuralgia Alliance
contact@pudendalneuralgiaalliance.org
© 2024 by Made with Wix ™ by founder (nonprofessional)
Paid for by founder until 501c3 status granted by IRS
​